WASHINGTON, Jan. 13, 2009 (LAWFUEL) — Finkelstein Thompson LLP
is currently investigating potential shareholder claims for breach of
fiduciary duty in connection with the proposed purchase of Advanced
Medical Optics, Inc. (“Advanced Medical”) (NYSE:EYE) by Abbott
Laboratories (“Abbott Labs”) (NYSE:ABT). Under the agreement announced
today, Abbott Labs will pay roughly $1.36 billion and will assume
certain debts, bringing the total value of the deal to approximately
$2.8 billion. This represents a 12% discount from the Company’s 52-week
high of $24.90.
The investigation is focused on the sufficiency of the merger
consideration, the adequacy of the disclosures, and the fairness of the
deal-protection provisions of the merger agreement. If you are
interested in discussing your rights as an Advanced Medical
shareholder, or have information relating to this investigation, please
contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050
or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients in
connection with securities and other finance-related litigation, and
has been appointed as lead or co-lead counsel in dozens of shareholder
class actions. Indeed, the firm has served in leadership roles in cases
that have recovered over $1 billion for investors and consumers. To
learn more about Finkelstein Thompson LLP, please visit our web site at
www.finkelsteinthompson.com.
